Sodium-glucose cotransporter-2 inhibitors: Expanding oral treatment options for type 2 diabetes mellitus

    loading  Checking for direct PDF access through Ovid


The number of patients with type 2 diabetes mellitus (T2DM) continues to increase in the United States. Glycemic control among patients with diabetes is important to prevent future complications, including microvascular and macrovascular disease. A novel class of medications, sodium-glucose cotransporter-2 inhibitors, presents an additional oral treatment option for patients with T2DM.

Related Topics

    loading  Loading Related Articles